An American Heart Association Presidential Advisory outlines an ambitious plan to increase rigorous research on initiatives aimed at providing food as medicine for chronic conditions.
A new study – using lab mice genetically modified with a human gene to shed light on a potential link between arsenic exposure and diabetes – revealed that while the male mice exposed to arsenic in drinking water developed diabetes, the female mice did not.
Patients who have drug-resistant tuberculosis have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine.
A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a previously unknown mechanism for insulin regulation in Type 2 diabetes, according to a new study by Weill Cornell Medicine investigators.
An analysis of beeswax in managed honeybee hives in New York finds a wide variety of pesticide, herbicide and fungicide residues, exposing current and future generations of bees to long-term toxicity.
In response to the COVID-19 pandemic, faculty in Cornell’s Public Health Program developed an innovative online training program to help boost skills in the public health workforce. A recent study recently reports that 94% of participants gained skills and knowledge they could apply directly to their work, and 86% developed a better understanding of public health.
Weill Cornell Medicine associate professor Gregory F. Sonnenberg has been awarded a five-year, $3.26 million grant from the National Institutes of Health to investigate the underlying mechanisms of inflammatory bowel disease.
Researchers at Weill Cornell Medicine have demonstrated how amyloid beta, a peptide associated with Alzheimer’s disease, can interact with a protein receptor on immune cells in the brain. This triggers a reaction that damages blood vessels and causes neurodegeneration.
Weill Cornell Medicine researchers and the TB Drug Accelerator have received two grants totaling $6.8 million from the Bill & Melinda Gates Foundation to study tuberculosis drug development.
During the COVID-19 pandemic, many U.S. hospitals had overcapacity intensive care units while other area hospitals had open ICU beds available, a phenomenon known as “load imbalance.”